Results 111 to 120 of about 6,212,144 (250)

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas   +7 more
wiley   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

HepaPlan: a CAD software for planning hepatic surgeries [PDF]

, 2015
López-Mir, F.; Naranjo Ornedo, V.; Verdú-Monedero, R.; Morales, S.; Brugger, S.; Pareja, E. (2015). HepaPlan: a CAD software for planning hepatic surgeries. International Journal of Computer Assisted Radiology and Surgery. 10(Suppl 1):S238-S239.
Verdú-Monedero, R., Brugger, S., Pareja, E., Naranjo Ornedo, Valeriana, Morales, Sandra, López-Mir, Fernando   +5 more
core  

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Quercetin‐zinc coordination polymer coated CaCO3 nanoparticles potentiate radiotherapy through reprogramming tumor immunosuppression

BMEMat, EarlyView.
Synthesis of QZCaCO3‐PEG to synergistically enhance the immunogenicity of radiotherapy through concurrent Zn2+‐induced cancer cell pyroptosis and Que‐mediated hypoxia amelioration through sequentially suppressing TGF‐β secretion and ECM deposition. Abstract Radiotherapy has demonstrated broad applications in treating solid tumors, but the hostile tumor
Chunjie Wang, Hengze Ding, Yu Hao, Honglin An, Ziliang Dong, Minming Chen, Yujie Zhu, Quguang Li, Bin Huang, Liangzhu Feng   +9 more
wiley   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Clinical applications of CD34+ progenitor cell immunophenotyping in myelodysplastic neoplasms—The CytHem SMD French network experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a risk of progression to acute myeloid leukemia. As the disease originates in hematopoietic stem and progenitor cells (HSPCs), flow cytometry (FCM) has emerged as a key approach to interrogate the bone ...
Nicolas Chapuis, Anne‐Catherine Lhoumeau, Stéphanie Mathis, Michel Ticchioni, Valérie Bardet, the French Working Group CytHem‐SMD   +5 more
wiley   +1 more source